Evoke Pharma, Inc.
EVOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $4 | $4 | $3 | $3 |
| % Growth | 14.2% | 21.8% | -6.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $4 | $3 | $3 |
| % Margin | 97.6% | 95.5% | 98.6% | 96.4% |
| R&D Expenses | $0 | $0 | $0 | $16,322 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $5 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$16,322 |
| Operating Expenses | $5 | $5 | $4 | $4 |
| Operating Income | -$1 | -$2 | -$1 | -$1 |
| % Margin | -26.6% | -41.5% | -42.3% | -36.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$2 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$1 | -$1 |
| % Margin | -27% | -41.9% | -42.4% | -36.1% |
| EPS | -0.45 | -0.62 | -0.51 | -0.8 |
| % Growth | 27.4% | -21.6% | 36.3% | – |
| EPS Diluted | -0.45 | -0.62 | -0.51 | -0.8 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 1 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -24% | -38.5% | -38.4% | -32.2% |